Cannabis and consumer goods firm Tilray outlines adjusted EBITDA projections amid strategic margin expansion efforts.
Tilray Brands Inc. (TLRY) announced plans to achieve $68M-$75M in adjusted EBITDA by fiscal 2027, driven by margin expansion initiatives. The projection reflects the company’s push to diversify beyond its core cannabis business into global consumer products and pharmaceuticals.
Management highlighted fiscal 2026 as a pivotal year, with progress toward profitability and operational efficiency. Prior-year adjusted EBITDA figures were not disclosed, but the 2027 target signals confidence in scaling revenue streams across multiple segments.
The announcement follows a broader industry trend of consolidation and cost optimization, as companies seek sustainable growth amid regulatory and market challenges.